Duchenne muscular dystrophy (DMD) is caused by changes in the dystrophin gene, which prevent the body from producing a protein called dystrophin, required for muscle health. Exon skipping is an approach that allows part of the impacted dystrophin gene to be skipped over in individuals with DMD to make a shorter form of dystrophin. Since dystrophin is essential for muscles to function well, a shorter version of the protein is better than no protein at all. Each exon-skipping treatment is designed for specific genetic changes within the dystrophin gene, so such therapies only apply to people who have a gene change amenable to skipping to a particular exon.ย
On October 14, 2026, Entrada Therapeutics shared news from two clinical trials testing new treatments for Duchenne. These trials are taking place at sites in the U.K. and Europe. There are currently no Canadian sites. Both are in early stages, and both offer reasons for hope as research moves forward. The first trial, called ELEVATE-45-201, is for individuals with confirmed DMD who are amenable to exon 45 skipping. The second trial, called ELEVATE-44-201, is for individuals with confirmed DMD who are amenable to exon 44 skipping.ย
First results from the ELEVATE-45-201 trial
The treatment being tested is called ENTR-601-45. About 9% of people with Duchenne worldwide have a dystrophin gene change that may be suited to exon 45 skipping. In this trial:
- Eight boys (all walking, all taking corticosteroids) took part. Six received the treatment and two received a placebo (‘fake drug, with no medicinal ingredients).
- These six boys received three doses of the lowest dose of ENTR-601-45 (5 mg/kg), given by IV once every six weeks.
After receiving this treatment, the investigators in the study reported the drug appeared ‘safe.’ This was the main goal. Headache was the most common side effect. One participant had vomiting and fever that resolved. None of the participants left the study, and no kidney or magnesium concerns were seen. They also confirmed the drug did lead to a small increase in dystrophin protein (by 0.10%), while the placebo group showed a slight decrease. This was expected at the starting dose. No measurable changes in muscle function have been reported yet, since this study is just in the early phase.ย
All eight participants have moved into the next phase, where everyone receives the treatment over a longer period. A second group is now receiving a higher dose (10 mg/kg), with results expected in the first half of 2027. A third group will receive up to 15 mg/kg.
This treatment is designed to be given once every six weeks, which works out to about nine infusions a year rather than the weekly infusions some current exon-skipping treatments require. That could mean fewer clinic visits and more time for school, work, and family life.
The ELEVATE-44-201 trial moves to its highest dose
The treatment being tested is called ENTR-601-44. About 8% of people with Duchenne worldwide have a dystrophin gene change that may be suited to exon 44 skipping. In this trial:
- In December 2025, the U.S. FDA granted Rare Pediatric Disease Designation. This means ENTR-601-44 is recognized as a promising therapy for a serious or life-threatening disease that primarily affects children and impacts fewer than 200,000 people in the U.S.
- An independent safety committee reviewed safety data from the second group of participants who were receiving a dose of12 mg/kg and recommended they move forward to the highest planned dose of 18 mg/kg. Results are expected by early 2027.
What this means for Canadians
Together, exon 44 and exon 45 skipping could apply to roughly 17% of the global Duchenne population. Canada has more than 800 boys and young men living with Duchenne, so some Canadian families may be watching these trials closely.
Defeat Duchenne Canada continues to advocate for timely, equitable access to promising treatments, so that when therapies like these are approved, Canadian families have the same opportunity for care as families in other countries. We will continue to follow these trials and share updates as new results become available.
If you have questions about what this news means for your family, please reach out to our team.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment:
